Navigation Links
Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
Date:3/2/2011

itors have the potential to be a novel drug with a new mechanism of action which will satisfy unmet medical needs for the millions of patients suffering from schizophrenia. We plan to accelerate our R&D activities for this compound in an effort to bring this novel medicine to patients as quickly as possible."

About Schizophrenia

Schizophrenia is a major neuropsychiatric disorder that affects over one percent of the world population with an illness that begins in late adolescence and lasts a lifetime. Its best known symptoms are "positive symptoms", which include hallucinations and delusions; but other mental functions are also affected, including social and motivational skills ("negative symptoms") and cognitive behaviors, like inattention and poor memory. Current antipsychotics are effective primarily on reducing positive symptoms but leave negative and cognitive symptoms untouched. Not only are current drugs incompletely effective, but they also have limiting side effects, including troublesome actions on motor function, weight gain, and metabolic symptoms (diabetes and hyperlipidemia), along with sedation, constipation, dizziness, and loss of bladder control. Few people with schizophrenia regain normal psychosocial function. The medical need in this disease area is enormous.

About PDE1 Inhibitors

These compounds are unique, orally available, investigational drugs being developed for the treatment of cognitive impairments accompanying schizophrenia and other neurological and neuropsychiatric disorders, including Alzheimer's disease, Attention Deficit Hyperactivity Disorder and Parkinson's disease.  These compounds also have the potential to improve motor dysfunction associated with these disorders. They potently inhibit the PDE1 enzyme in a competitive manner with sub-nanomolar affinity for this subfamily. These compounds are very selective for the PDE1 subfamily relative to other PDE subfam
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
2. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
3. Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
4. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
5. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
6. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
7. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
8. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
9. Reportlinker Adds Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets
10. Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
11. The Blanchette Rockefeller Neurosciences Institute Identifies Groundbreaking New Therapies for Prevention and Treatment of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  Today the U.S. Food and Drug Administration (FDA) ... of serogroup B meningococcal disease in individuals ... which received FDA approval in October, represent a significant ... "I have heard over and over from ...
(Date:1/23/2015)... 2015 A lot of discussion in the medical community ... illnesses, injuries, or conditions. As medical science advances, doctors and ... ones that they consider to be more cutting edge. Yet, ... textbook method of treatment that stands out as the best ...
(Date:1/23/2015)... to Fight Chronic Disease (PFCD) released a public opinion poll of ... study analyzing the impact of increased cost sharing on patient adherence ... educate policy makers and the public on the costs of chronic ... the Iowa healthcare exchange could be improved ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2No One-Size-Fits-All Remedy for Hernia Correction 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3
... 27, 2011 Pepto-Bismol announced today that for the second ... white and … PINK? In an act of true gastro-patriotism, ... Nathan,s Famous Fourth of July International Hot Dog Eating Contest ... To make this contest a celebration to remember, Pepto-Bismol has ...
... Recent findings published in the scientific journal Leukemia ... with standard anti-leukemia agents, the biological activity of Leukothera ... Biomed, Inc., showed synergistic anti-leukemia effects. ... demonstrated that combining Leukothera TM with ...
Cached Medicine Technology:Pepto-Bismol and Nick Cannon Heat Things up at this Year's Nathan's Famous Fourth of July International Hot Dog Eating Contest 2Pepto-Bismol and Nick Cannon Heat Things up at this Year's Nathan's Famous Fourth of July International Hot Dog Eating Contest 3Recent Study Shows Leukothera™ Combined with Other Agents Has Enhanced Anti-Leukemia Effects 2
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz Chiropractic ... treated just about every type of injury that can result from ... same twenty-plus years, the team at Doctors on Liens ... possible doctor. With the combined breadth of experience between ...
(Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Compare-autoinsurance.org has released a ... insured by an auto insurance policy . , Some ... policy. Clients should check the newly released blog post to see ... cars and dangerously damaged vehicles are some of the cars that ...
(Date:12/26/2014)... December 26, 2014 The US represents the ... report. In 2013, GlobalData’s forecast estimates that sales of branded ... market due to the high incidence of the disease, high ... 5EU, Japan, and China. Increased sales of CRC therapies over ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... laser pointers have become a popular consumer item, delivering light ... have circulated on the Web about the potential hazards of ... at the National Institute of Standards and Technology (NIST) puts ... found that a green laser pointer emitted almost twice its ...
... HealthDay Reporter , TUESDAY, Aug. 3 (HealthDay News) ... their homocysteine levels may not be protected from second strokes ... studies found an association between homocysteine, an amino acid, in ... attack. Vitamin B supplements lower homocysteine levels, but whether this ...
... in the emergency room reduced by half the chances that ... according to a study published Aug. 4 in a theme ... . The special issue on violence and human ... researchers who immersed themselves at the Hurley Medical Center Emergency ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... As of 2009, almost 3 in every 10 adults ... in 2007, according to a new government report released Tuesday. ... Disease Control and Prevention (CDC), also found that between 2007-2009, ...
... study of breast cancer survivors may help physicians ease a ... Eva Sevick, Ph.D., Director of the Center for Molecular Imaging ... (UTHSC), and Caroline Fife, M.D., Director of the Memorial Herman ... Their paper appears in the inaugural issue of ...
... , Two University of Iowa biologists have published a paper ... the hope of one day learning more about human developmental ... Proceedings of the National Academy of Sciences . ... of biology in the UI College of Liberal Arts and ...
Cached Medicine News:Health News:NIST researchers measure high infrared power levels from some green lasers 2Health News:Vitamin B May Not Guard Against Second Stroke, Heart Attack 2Health News:Vitamin B May Not Guard Against Second Stroke, Heart Attack 3Health News:University of Michigan study: Pep talk to teens in the ER helped reduce violence, alcohol misuse 2Health News:University of Michigan study: Pep talk to teens in the ER helped reduce violence, alcohol misuse 3Health News:Number of Obese Adults Keeps Rising, CDC Says 2Health News:Number of Obese Adults Keeps Rising, CDC Says 3Health News:New imaging technique could help physicians ease the aftermath of breast cancer 2Health News:U. Iowa biologists publish findings on cell interactions 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: